BioWorld

June 12, 2006

View Archived Issues

Pozen's Stock Crushed On Trexima Approvable Letter

The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today) Read More

CoGenesys' $55M Financing Makes HGS Spinout Official

Read More

Merger With SIGA Would Give PharmAthene ST-246, Listing

Read More

Genentech: Cancer Competition Part Of 'Moving The Field Along'

Read More

Other News To Note

Read More